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ABSTRACT: α-Synuclein ﬁbrils are considered a hallmark of
Parkinson’s disease and other synucleinopathies. However, small
oligomers that formed during the early stages of α-synuclein aggregation
are thought to be the main toxic species causing disease. The formation
of α-synuclein oligomers has proven diﬃcult to follow, because of the
heterogeneity and transient nature of the species formed. Here, a novel
bead-based aggregation assay for monitoring the earliest stages of α-
synuclein oligomerization, α-Synuclein−Confocal Nanoscanning
(ASYN-CONA), is presented. The α-synuclein A91C single cysteine
mutant is modiﬁed with a trifunctional chemical tag, which allows
simultaneous ﬂuorescent labeling with a green dye (tetramethylrhod-
amine, TMR) and attachment to microbeads. Beads with bound TMR-
labeled α-synuclein are then incubated with a red dye (Cy5)-labeled
variant of α-synuclein A91C, and EtOH (20%) to induce aggregation.
Aggregation is detected by confocal scanning imaging, below the equatorial plane of the beads, which is known as the CONA
technique. On-bead TMR-labeled α-synuclein and aggregated Cy5-labeled α-synuclein from the solution are quantitatively
monitored in parallel by detection of ﬂuorescent halos or “rings”. α-Synuclein on-bead oligomerization results in a linear
increase of red bead ring ﬂuorescence intensity over a period of 5 h. Total internal reﬂection ﬂuorescence microscopy was
performed on oligomers cleaved from the beads, and it revealed that (i) oligomers are suﬃciently stable in solution to
investigate their composition, consisting of 6 ± 1 monomer units, and (ii) oligomers containing a mean of 15 monomers bind
Thioﬂavin-T. Various known inhibitors of α-synuclein aggregation were used to validate the ASYN-CONA assay for drug
screening. Baicalein, curcumin, and rifampicin showed concentration-dependent inhibition of the α-synuclein aggregation and
the IC50 (the concentration of the compound at which the maxiumum intensity was reduced by one-half) were calculated.
Parkinson’s disease and other synucleinopathies arecharacterized by the misfolding and aggregation of α-
synuclein. α-Synuclein is a small presynaptic protein whosemain
function is believed to occur at the presynaptic terminals and
may play a role in regulating synaptic transmission.1 Its amino-
acid sequence consists of three distinct regions with diﬀerent
properties. The N-terminus, which is deﬁned by residues 1−60,
contains an imperfect repeated sequence (KTKEGV) involved
in the amphiphilic α-helical structure adopted when bound to
lipids.2 The nonamyloid component (NAC), region, which is
deﬁned by residues 61−95, is highly hydrophobic and forms the
core of the highly organized ﬁbril structures.3 The C-terminus,
which is deﬁned by residues 96−140, is negatively charged and
contains several proline residues, making it very ﬂexible. This
region is found to be unstructured in α-synuclein ﬁbrils.4
α-Synuclein exists primarily as an unfolded monomer in
equilibrium alongside some partially folded monomers and
multimers, depending on the local environments of the
protein.5−8 In disease, α-synuclein is believed to misfold,
acquiring a conformation prone to aggregation that leads to the
formation of highly organized ﬁbrils.9 The structure of mature
ﬁbrils have recently been established in detail by solid-state
NMR4 and cryo-EM10 to be Greek key-like. Fibrillation of α-
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synuclein is described as occurring in three phases, similar to the
formation of other amyloid ﬁbrils. The ﬁrst stage of ﬁbrillation is
called the nucleation or lag phase, where the protein undergoes a
change in conformation that allows the formation of small
oligomers. The second phase is the elongation, in which the small
oligomers rearrange into a conformation with a greater β-sheet
content, forming protoﬁbrils that subsequently elongate,
forming the ﬁbrils. The ﬁnal phase is the stationary phase, in
which ﬁbrils reach equilibrium with the other α-synuclein
species in solution.11 The kinetics of ﬁbril formation are
classically detected by ﬂuorescence emission intensity changes
of solvatochromic dyes such as thioﬂavinT, ThT, which exhibit
enhanced ﬂuorescence upon binding to β-sheet-rich ﬁbrils. α-
Synuclein ﬁbrils are the species found to be the main
components of Lewy bodies and Lewy neurites in the brains
of patients.11,12 However, early oligomers, formed during the lag
phase, are thought to be the main toxic species in disease.13,14
To date, the formation and structure of α-synuclein oligomers
have proven diﬃcult to investigate, because of their transient
state and heterogeneous characteristics.15 The shape, size, and
conformation of various diﬀerent oligomers, and their kinetics of
formation, have been described in the literature, but a consensus
on the most disease relevant species has not yet been reached.15
Several groups have described the existence of two diﬀerent
types of oligomers on the pathway to ﬁbril formation.16−19 The
earliest oligomers detectable in the pathway have been shown to
be smaller and less compact than the subsequent ones. Some
studies have suggested that both types of oligomers are able to
form ﬁbrils,16,19 in disagreement with other studies that
suggested that just one of the oligomers is able to continue
through to ﬁbril formation.20 It is not known if these studies
were describing the same or diﬀerent types of oligomer.
Evidence of heterogeneity of oligomers has been reported
many times. The diﬀerent nature of these oligomers could
explain the diﬀerent ﬁbrillation propensities. To our knowledge,
the kinetics of the full oligomerization process has been
quantiﬁed twice, both by single-molecule techniques. One by
direct measuring of the aggregation of labeled α-synuclein,20 and
the other one by measuring ThT anisotropy.21 Both studies
focus on the conformational changes of the oligomers observed,
describing the interconversion between two diﬀerent types of
oligomers and not on the development of an assay for HTS.
The variability of the oligomers formed could potentially be
explained by the diﬀerent experimental conditions used to
induce the oligomerization process. To date, it appears that no
universal standard detection method for oligomer formation has
been established.15
This work describes a novel assay for monitoring early α-
synuclein oligomerization on-bead, α-synuclein−confocal nano-
scanning (ASYN-CONA). On-bead screening is a well-validated
screening technique for the detection of the binding of small
molecular entities synthesized on bead to target proteins in
solution.22−25 Confocal nanoscanning (CONA) relies on the
imaging of a monolayer of beads, using a scanning confocal
microscope focused below the equatorial plane of the beads and
scanned through the entire well, generating a cross section of the
beads.26−28 When ﬂuorescently labeled target protein is bound
to the bead, a “halo” or “ring” is observed. Bead-based screening
oﬀers a series of advantages, including sensitivity, versatility,
miniaturization, statistical signiﬁcance, and multiplexing. The
advantages of the bead-based screening platform have been
exploited to develop ASYN-CONA, which focuses on studying
the early oligomerization process of intrinsically unfolded
proteins, exempliﬁed with α-synuclein.
■ MATERIALS AND METHODS
All commercially available reagents were purchased from
Sigma−Aldrich or VWR Scientiﬁc, unless otherwise stated,
and used as received taking the determined concentration after
quality control by HPLC and LCMS.
Confocal Imaging. Bead images were taken on an Opera
High Content screening system (PerkinElmer), using a 20× air
objective, NA 0.45, with a 384 well plate (SWISSCI, Code
PS384B-G175) and detection was performed by Peltier-cooled
CCD cameras with 1.3 megapixel. The focal height was set to 30
μm above the well plate surface. A three-exposure setup was
used, all in camera 2 with primary dichroic 445/561/640:
exposure one, cw laser 561 nm, detection dichroic 568sp for
camera 2, ﬁlter 585/40; exposure two (bright-ﬁeld), top
illumination, 50% LED, 160 ms exposure time, detection
dichroic 650sp for camera 2, ﬁlter 690/70; and exposure three,
cw laser 640 nm, detection dichroic 650sp for camera 2, ﬁlter
690/70. The speciﬁc laser powers and exposures times are
speciﬁed in each experiment. The wells were imaged as 77
overlapping (20%) images over the entire well area, avoiding the
edges.
Stitching. Images were stitched using Fiji software29 with a
batch stitching macro utilizing the ImageJ plugin Grid/Mosaic
stitching.30
Image Analysis. Bead Ring Evaluation and Analysis of Data
software (BREAD), developed in Auer lab, was used for the
analysis of all image data (a manuscript describing BREAD in
more detail is in preparation). In brief, beads are individually
detected in each channel within a radius range deﬁned by the
number of pixels, here between 60 and 110. Where images are
dark, or beads nonﬂuorescent, the bright-ﬁeld channel is used to
specify the location of beads in the ﬂuorescent image, so that
they can still be included for analysis to ensure correct statistical
evaluation. Bead ring intensity is calculated from n proﬁles taken
from each bead. In the analysis of the images in this project, n
was always 10. The maxima of the intensity proﬁles at the two
edges of the beads were averaged, and the 20th−80th percentiles
of the proﬁle intensity between these two points was subtracted
to account for the intensity of the center of the bead. This
number was referred to as the bead ring intensity. Bead ring
intensity from each bead is calculated as the average of all the
proﬁles of each bead. Mean bead ring intensity of each well in
each channel is calculated as the average ring intensity of all the
beads in the well. Ratiometric quantiﬁcation was calculated by
dividing the ring intensity in two diﬀerent channels on an
individual bead basis. Outlying beads (<5%) were deleted and
not considered for the quantiﬁcation. Beads were considered to
be outlying if a bead was badly stitched or broken, when it was
out of focus, when no ring was observed under exposure one, or
when the bead brightness was at least 1 order of magnitude
larger than average.
α-Synuclein Aggregation Assay. Ni-NTA agarose beads
(Qiagen, No. 30250) were sieved manually using 120 μm
(Merck Millipore, No. NY2H04700) and 100 μm (Falcon cell
strainer, No. 352360) ﬁlters and beads with sizes between 100
μm to 120 μm were used for all of the on-bead experiments.
Beads were stored in 20% EtOH in water and washed prior to
any experiment with buﬀer (20 mM Tris, 100 mM NaCl, pH
7.1) three times by removing supernatant and adding more
buﬀer and kept in a 50% slurry solution. Aliquots of protein
Analytical Chemistry Article
DOI: 10.1021/acs.analchem.8b03842
Anal. Chem. 2019, 91, 5582−5590
5583
stored at −80 °C were defrosted and used on the day. For the
incubation of the α-synuclein-A91C-HTM with the beads, 275
μL of protein solutions for ﬁnal concentrations of 0, 500, 200,
100, 50, and 25 nMwere prepared and 25 μL of 50% slurry beads
were added. The solutions were shaken at 1000 rpm and 22 °C
for 20 min and washed 3 times to remove any unbound protein.
Aliquots of 10 μL were taken and imaged at this stage. For the
aggregation assays, α-synuclein-A91C-Cy5 (500 nM ﬁnal
concentration) and EtOH (0 for the control or 20% ﬁnal
concentration) were added. The reaction was shaken at 1000
rpm for a maximum of 6 h at 22 °C. Aliquots of 20 μLwere taken
every hour and imaged stitched and analyzed as described
above: exposure one, 1500 μW and 120 ms; exposure two, LED
50% and 160 ms; exposure three, 1000 μW and 120 ms.
Elution of α-Synuclein Oligomers from Beads. After 5 h
of incubation of the beads (1 mL of 500 nM aS-A91C-HTM, 2.5
μM aS-Cy5 and 20% EtOH) shaking at 22 °C, the supernatant
was removed and the beads washed 3 times with 20 mM Tris,
100 mM NaCl, pH 7.1. 300 mM imidazole, 20 mM Tris, 100
mM NaCl, pH 7.1 (100 μL) was added to elute the oligomers
from the beads. The solution was collected, ﬂash frozen, and
stored at −20 °C until required.
Sample Preparation for Single-Molecule TIRF. Micro-
scope coverslips were prepared as described in the Supporting
Information. Eluted α-synuclein was diluted to a concentration
of 10 nM in 20 nm ﬁltered buﬀer (20 mM Tris, 100 mM NaCl,
pH 7.1) with 50 μMThioﬂavin-T (Sigma−Aldrich. Product No.
T3516) (for single aggregate visualization by enhancement
(SAVE) imaging),31 before being added to the poly-L-lysine
coated coverslip. Following 10 min of incubation, the coverslips
were rinsed three times with 20 nm ﬁltered buﬀer (20 mM Tris,
100mMNaCl, pH 7.1), and imaged on the single-molecule total
internal reﬂection ﬂuorescence (TIRF) microscope.
Single-Molecule Imaging. Single-molecule imaging was
performed using a custom-built, bespoke single-molecule TIRF
microscope, which restricts the illumination to within 200 nm of
the sample slide. The ﬂuorophores were excited at either 405 nm
(Thioﬂavin-T), 561 nm (TMR), or 638 nm (Cy5). Collimated
laser light at wavelengths of 405 nm (Cobolt MLD Series 405-
250 Diode Laser System, Cobolt AB, Solna, Sweden), 561 nm
(Cobolt DPL Series 561-100 DPSS Laser System, Cobolt AB,
Solna, Sweden), and 636 nm (Cobolt MLD Series 638-140
Diode Laser System, Cobolt AB, Solna, Sweden) were aligned
and directed parallel to the optical axis at the edge of a 1.49 NA
TIRF objective (CFI Apochromat TIRF 60XC Oil, Nikon,
Japan), mounted on an inverted Nikon TI2 microscope (Nikon,
Japan). The microscope was ﬁtted with a perfect focus system,
which autocorrects the z-stage drift during imaging. Fluo-
rescence collected by the same objective was separated from the
returning TIR beam by a dichroic mirror (Di01-R405/488/
561/635 (Semrock, Rochester, NY, USA), and was passed
through appropriate ﬁlters (405 nm: BLP01-488R-25 (Semrock,
Rochester, NY, USA), 561 nm: LP02-568-RS, FF01-587/35
(Semrock, Rochester, NY, USA), 638 nm: FF01-692/40−25
(Semrock, Rochester, NY, USA). The ﬂuorescence was then
passed through a 2.5× beam expander and recorded on an
EMCCD camera (Delta Evolve 512, Photometrics, Tucson, AZ,
USA) operating in frame transfer mode (EMGain = 11.5 e−/
ADU and 250 ADU/photon). Each pixel was 103 nm in length.
Images were recorded with an exposure time of 50 ms with 638
nm (∼50 W cm−1) illumination, 561 nm illumination (∼50 W
cm−1), followed by 405 nm excitation (∼100 W cm−1). The
microscope was automated using the open source microscopy
platform Micromanager.
Testing Inhibitors Using the ASYN-CONA Assay.
Selegiline, curcumin, rifampicin, dopamine, baicalein, and
nicotine were analyzed by HPLC and LCMS prior to use. The
experiments were performed as described above. In more detail,
the following conditions were applied. α-Synuclein-A91C-HTM
was used at 100 nM and α-synuclein-A91C-Cy5 was used at 500
nM. The compounds were dissolved in EtOH and added to a
ﬁnal concentration of compound of 50 μM and 20% EtOH.
Control samples with no compound, no compound, and no α-
synuclein-A91C-HTM or no EtOH were included in the
experiment. Imaging conditions were the same as described
above.
For measurement of the concentration-dependent inhibition
of baicalein, curcumin, and rifampicin, the experiments were
performed exactly the same but with the addition of diﬀerent
concentrations of the inhibitors dissolved in EtOH.
With regard to IC50 ﬁtting, where IC50 represents the
concentration of the compound at which the maxiumum
intensity (Imax) was reduced by one-half, the mean bead ring
intensity data were plotted using GraFit v7.0.3 (Erithacus
Software Limited).50 The standard IC50 equation in GraFit,
= −
+
+
( )
y
I I
I
1 x
n
max min
IC
min
50
was used to perform a four-parameter ﬁt of the data to obtain
IC50 values for individual compounds, where y is the observed
mean bead ring intensity; Imax and Imin are the maximum and
minimum mean bead ring intensities, respectively; IC50 is the
concentration of the compound at which Imax was reduced by
half; n is the slope of the ﬁt; and x is the compound
concentration.
■ RESULTS AND DISCUSSION
Attachment of α-Synuclein to Beads. A critical require-
ment for the development of the bead-based α-synuclein
aggregation assay was the attachment of ﬂuorescently labeled α-
synuclein to microbeads. For this purpose, a trifunctional
chemical tag was synthesized, enabling the simultaneous
ﬂuorescent labeling of the protein and speciﬁc functionalization
with a reactive group to attach the protein to beads. The tag
required three diﬀerent functionalities: a reactive group to
covalently bind to the protein, a ﬂuorophore, and a speciﬁc
group to bind to the beads (Figure 1). The functionalization was
achieved by a synthetic trifunctional tag (HTM, 1). The three
functionalities of the tag include a maleimide for protein
labeling;32 a His6-tag for bead attachment, and tetramethylrhod-
amine (TMR)33 dye for ﬂuorescent properties (Figure 1A). In
brief, HTM (1) was successfully synthesized using standard
Fmoc solid-phase peptide synthesis (see the Materials and
Methods section).
Since α-synuclein lacks cysteine residues in its sequence, a
single cysteine mutation was generated to provide a speciﬁc
reactive point for protein functionalization via a maleimide.
Single-cysteine mutants of α-synuclein have been extensively
used for its labeling and have shown no eﬀect on its behavior
when the mutation is located at the end of the NAC region or on
the C-terminus of the protein (residues 90−140).17,18,20,34−37
Thirunavukkuaras et al. have used solvatochromic dyes at
diﬀerent positions in α-synuclein to study conformational
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changes during aggregation.34 The conclusions provided
valuable information about regions of the protein in proximity
to each other at diﬀerent stages of the aggregation process,
allowing the selection of labeling position that would have low
impact on the aggregation.
For ASYN-CONA assay development, a cysteine was
introduced in position A91. Brieﬂy, α-synuclein-A91C was
expressed in E. coli and puriﬁed by acid precipitation, followed
by anion exchange chromatography (see the Materials and
Methods section).
TMR was used as a dye, because of its optical stability and
great brightness. It is of critical importance for the assay quality
that the intensity of the TMR emission deﬁnes single bead
loading by α-synuclein.
α-Synuclein-A91C was labeled with the trifunctional tag (1)
and incubated with Ni-NTA agarose beads presieved to
homogeneous sizes (100−120 μm) to allow optimized ring
detection and quantiﬁcation. Imaging of the TMR tagged on-
bead α-synuclein (α-synuclein-A91C-HTM) was performed on
a PerkinElmer Opera high-content screening system. The
presence of protein on-bead was observed through a ﬂuorescent
ring around each bead (Figure 2). The attachment of TMR-
labeled α-synuclein was shown to be concentration dependent
(Figure 2). When the beads were incubated with increasing
protein concentrations the bead ring intensities increased
linearly as shown on Figure 2.
On-Bead Aggregation Assay. ASYN-CONA is performed
on microbeads to which TMR-labeled α-synuclein is attached as
described above. Aggregation is induced in the presence of Cy5-
labeled α-synuclein in solution (Figure 3). On-bead and
aggregated α-synuclein are observed via the ﬂuorescence
properties of the diﬀerent dyes that form a ﬂuorescent halo on
the bead surface. The oligomerization is quantiﬁed via the
increase of the ﬂuorescent intensity of the bead rings.
α-Synuclein aggregation has often been described as a very
heterogeneous process.15 Many aggregating agents have been
reported, such as metal ions,38,39 organic solvents,40,41 acid-
ity,42,43 temperature,43 sodium dodecyl sulfate (SDS),44 and
liposomes.45 For the ASYN-CONA on-bead aggregation assay,
20% EtOH proved to be the most reliable aggregation inducing
agent.41 Various other experimental conditions were tried, but
none showed equally consistent results as EtOH. In the presence
of DMSO, inhomogeneous bead rings were observed but did not
increase in intensity over time (data not shown).
Following the attachment of the TMR-labeled α-synuclein to
the microbeads, the aggregation of orthogonally labeled α-
synuclein with Cy5 can be monitored.
Beads were conjugated with α-synuclein-A91C-HTM at
diﬀerent concentrations (25, 50, 100, 250, and 500 nM) and
examined by confocal scanning microscopy. After this ﬁrst step,
α-synuclein-A91C-Cy5 (500 nM) and EtOH (20%) were added
to the bead solutions to induce aggregation of the Cy5-labeled α-
synuclein on the TMR-labeled α-synuclein on bead. The
Figure 1. (A) Structure of the HTM trifunctional tag (1). The tag
consists of a His6-tag, for binding to Ni-NTA beads; a ﬂuorophore
(TMR); and a protein linkage point (maleimide). (B) The diﬀerent
steps required to attach the protein to the microbeads. First, the protein
is covalently modiﬁed with the trifunctional tag. Subsequently, the
functionalized protein is attached to microbeads, which will be used in
the ASYN-CONA assay.
Figure 2. Ring intensity is linearly proportional to the amount of α-
synuclein-A91C-HTM incubated with the beads. Mean bead ring
intensity in the TMR channel (λex = 561 nm, λem = 585/40 nm) is
represented as a function of the concentration of α-synuclein-A91C-
HTM (0, 25, 50, 100, 250, and 500 nM) used for attachment to the Ni-
NTA agarose beads. Fitted line (red) represents linear regression of the
data (R2 = 0.9984). The two diﬀerent data points for each
concentration originates from beads functionalized on the same day.
Figure 3. ASYN-CONA, a bead-based assay for α-synuclein
aggregation. Upper panel shows a schematic representation of the
assay. Lower panel shows example images acquired at diﬀerent stages of
aggregation. In the image on the left, α-synuclein labeled with TMR
(green) is attached to the beads, which is observed as rings in
ﬂuorescence emission channel for TMR. Cy5-labeled α-synuclein is
added to the solution but no bead rings are observed in Cy5
ﬂuorescence emission channel (red), because aggregation has not yet
started. In the middle image, upon treatment with an aggregation
inducing agent, red rings of Cy5-labeled α-synuclein begin to form
around the bead. In the image on the right, over time, α-synuclein
aggregates increase in size, leading to an increase in the ﬂuorescence
emission ring intensity in the Cy5 channel.
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aggregation process was followed for 5 h while shaking. Aliquots
of the beads were taken every hour and imaged by confocal
scanning. The images were taken in two diﬀerent ﬂuorescent
emission channels adapted to the ﬂuorescent properties of Cy5
(ex. 640 nm, em. 690/70 nm) and TMR (ex. 561 nm, em. 586/
40 nm); and a bright-ﬁeld channel (see the Materials and
Methods section). The bead images were then analyzed with a
custom-developed software known as Bead Ring Evaluation and
Analysis of Data (BREAD), for quantiﬁcation of the bead ring
intensities in the diﬀerent detection channels. BREAD detects
the presence and locations of beads in all ﬂuorescent and bright-
ﬁeld channels, and then correlates and combines them. This
reduces the risk that insuﬃciently ﬂuorescent beads are excluded
from the analysis. Intensity proﬁles (in this study, 10) are
deﬁned from each bead through the bead diameter, and the peak
maxima of the proﬁles quantiﬁed and the bead interior
ﬂuorescence subtracted. The average of the proﬁles is calculated
to reveal the individual bead ring intensity. The discrete bead
ring intensities of all beads in a well are then averaged to produce
the mean bead ring intensity in the well under study. Variable
protein loading between beads is corrected via calculation of the
ratios between the two ﬂuorescence emission channels on a
single-bead basis.
Two control experiments were included. In the ﬁrst control
experiment, the beads lacking preconjugated α-synuclein-A91C-
HTM were exposed to the aggregation mix described above, to
observe any unspeciﬁc interactions of the protein in solution
with the beads in the presence of EtOH (Figure 4, black squares,
0 nM). The second control experiment was performed following
an identical protocol to the aggregation experiment described
above but in the absence of EtOH, to observe any noninduced
aggregation processes that might occur (Figure 4, red circles, no
EtOH). Both control experiments showed no increase of the
mean bead ring intensity of Cy5, compared to the experiments in
the presence of both α-synuclein-A91C-HTM and EtOH.
Quantiﬁed bead ring intensities in the diﬀerent detection
channels correlate with the amount of the protein on the bead
surface. As expected, the bead ring intensity measured via the
ﬂuorescence emission intensity detected in the TMR channel
corresponding α-synuclein-A91C-HTM conjugated to beads
remains stable during the course of the experiment (Figure S1 in
the Supporting Information). Over time, the bead ring intensity
measured via the ﬂuorescence emission intensity detected in the
Cy5 channel increases linearly, as shown in Figure 4. This
increase of bead ring intensity represents the rate of α-synuclein-
A91C-Cy5 aggregation onto bead-conjugated α-synuclein-
A91C-HTM under the experimental conditions. The apparent
rates of α-synuclein-Cy5 aggregation were dependent on the
concentration of α-synuclein-HTM conjugated to the beads
(see Figure 4, as well as Figure S2 in the Supporting
Information) in a concentration range tested between 25 nM
and 500 nM of α-synuclein-A91C-HTM. When the ratio
between aggregated α-synuclein-A91C-Cy5 and on-bead α-
synuclein-A91C-HTM was ≥5:1 (500 nM and 100 nM,
respectively), the aggregation reaction followed a linear trend.
At ratios of 1:1 or 2:1, the linear dependency began to deviate
from linearity, most likely due to the depletion of available α-
synuclein-Cy5 in solution. The mean bead intensity of α-
synuclein-Cy5 over time was ﬁtted by linear regression, as shown
in Table 1.
When the experiments were performed at 1:1 and 1:2 ratios of
protein on bead to protein in solution, the observed aggregation
rate is dependent on both the α-synuclein aggregation itself and
the depletion of the protein in solution. On the other hand, in
systems working at higher ratios, 1:5 to 1:20, the eﬀect of protein
depletion on the rate of α-synuclein aggregation rate is less
signiﬁcant, and the aggregation kinetics appear to be linear.
Under the experimental conditions examined here, the
simplest model to explain the linear on-bead aggregation
requires that each α-synuclein can only bind two other α-
synuclein proteins (Figure 5A). In this model, the two potential
mechanisms include one in which the interaction site is
hampered by the bead on the α-synuclein-A91C-HTM and an
Figure 4. α-Synuclein-A91C-Cy5 aggregates in a linear manner. The
plot shows the mean bead ring intensity detected in the Cy5 emission
channel, representing the aggregated α-synuclein-A91C-Cy5 on the α-
synuclein-HTM conjugated beads. Diﬀerent colors and symbols
represent the diﬀerent concentrations of α-synuclein-A91C-HTM
used to incubate with the beads. The rate of increase of the mean bead
ring intensity is dependent on the concentration of the conjugated
protein to the bead. Lines represent a linear regression of the data (data
shown in Table 1). Six independent replicates of the experiment were
performed in total, all of them showing the reproducibility of the assay;
for the sake of clarity, only a single repetition of the experiment is
shown, with the standard deviation corresponding to the individual
experiment. After incubation of the beads with α-synuclein-A91C-
HTM (500, 250, 100, 50, and 25 nM) and washing, α-synuclein-A91C-
Cy5 (500 nM) and EtOH (20%) were added to the beads and left
shaking. Aliquots were taken at time intervals for imaging and
quantiﬁcation.
Table 1. Observed Aggregation Rates of α-Synuclein-A91C-
Cy5 (500 nM), as a Function of the Amount of α-Synuclein-
A91C-HTM on Beada
Intercept (AU) Slope (h−1) Statistics
αS-A91C-HTM value std er value std er adj. R2
0 nM 1.82 0.15 9.78 2.09 0.81
500 nM (no EtOH) 1.85 0.34 6.01 1.11 0.85
500 nM 2.19 0.36 326.94 17.56 0.99
250 nM 2.06 0.18 221.31 8.74 0.99
100 nM 2.45 0.07 149.22 2.74 1.00
50 nM 2.31 0.08 67.24 1.68 1.00
25 nM 2.34 0.07 51.07 1.16 1.00
aResults from the ﬁtting of the mean bead ring intensity in the Cy5
emission channel of data from Figure 4 for the diﬀerent
concentrations of α-synuclein-A91C-HTM incubated with the
beads, using y = a + bx as a linear equation. At higher concentrations
of α-synuclein-A91C-HTM, the slope of the ﬁt increases, and the
adjusted R2 decreases.
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alternative in which it is not (Figure 5A(i) and (ii). The
characteristic kinetics of formation would diﬀer only by changes
in the gradient of the curve (Figure 5B). Any larger number of
binding surfaces on the α-synuclein would lead to a character-
istic pattern for aggregation corresponding to a geometric series
(Figure 5B), which does not match the observed results. A one-
to-one binding event cannot be discarded , because it would also
match the observed results. Another possible explanation for the
linear aggregation would involve unspeciﬁc binding of α-
synuclein-A91C-Cy5 to the microbeads. However, this model
does not correspond with the lack of increase in intensity as a
function of time when no α-synuclein-A91C-HTMwas attached
to the beads (Figure 4, black squares, 0 nM).
In summary, the observed linear increase of the aggregated
protein, ratios of ≥5:1 of in solution to on-bead α-synuclein,
indicates that the mechanism of early aggregation under these
experimental conditions might be more homogeneous and
controlled than often assumed. Further characterization of the
species formed on-bead is required to better understand the
oligomerization mechanism detected under these experimental
conditions.
The comparison with previously published results such as
Munishkina et al.41 represents a challenge due to the diﬀerent
experimental conditions of the two systems. The results
described by Munishkina are based on the increase of
ﬂuorescence of ThT upon binding to α-synuclein ﬁbrils. It
shows that the aggregation follows a sigmodal curve with a short
lag phase in the presence of 20% EtOH. The 5 h time frame of
the assay described here encompasses the lag phase and the
beginning of the increase of ﬂuorescence in the ThT, which
correspond to the early aggregation of α-synuclein. However,
care must be taken when comparing the two results, since
diﬀerent experimental conditions, such as concentration and
temperature, among others, change the aggregation properties
substantially.15
Two other α-synuclein mutants, V3C and I112C, were tested
using the same assay as for A91C. Both α-synuclein mutants
showed a linear aggregation process (data not shown), but with
slightly diﬀerent rates. The changes in the rate could be due to
diﬀerent aggregation propensities of the mutants, the relative
position of the dyes, or other factors. However, the linearity
observed is unaﬀected by the position of the mutation. The
eﬀect of position of the mutations is under further study and will
be part of future research.
Imaging of Oligomers by Single-Molecule Total
Internal Reﬂection Fluorescence (TIRF) Microscopy.
Single-molecule total internal reﬂection ﬂuorescence (TIRF)
microscopy has previously been used to study the aggregation of
α-synuclein.31,46,47 Utilizing the diﬀerent ﬂuorescent wave-
lengths of the ﬂuorophores used in the assay (TMR and Cy5), it
is possible to measure their oligomerization by observing the
coincidence of the two α-synuclein species. In this study,
aggregated on-bead α-synuclein (both HTM and Cy5 labeled)
was eluted and imaged (Figures 6A−C). The coincidence
between TMR (λex = 561 nm) and Cy5 (λex = 638 nm) indicates
the presence of an oligomer, which are visible as yellow spots in
Figure 6B and are highlighted in Figures 6D−F, in which only
the coincident spots are shown. The association quotient,Q (see
data analysis in the Supporting Information) is a measure of the
level of coincidence of the two species. For these samples, Q =
Figure 5.Models of on-bead α-synuclein aggregation: (A) α-synuclein
is modeled to have two binding sites and the aggregation is shown as a
linear increase of the ﬂuorescence of the Cy5 labeled α-synuclein
(bottom left) (i) one of the binding surfaces on α-synuclein-HTM is
hampered by the microbead, and (ii) both binding surfaces on α-
synuclein-HTM are exposed for aggregation); (B) α-synuclein is
assumed to have three binding sites and the aggregation is shown as an
increase in ﬂuorescence intensity, following a geometric series (bottom
right). The graph shown as an inset in panel (B) is set to the same scale
as panel (A), for the sake of comparison. [Red features represent Cy-5-
labeled α-synuclein, and green features represent HTM-labeled α-
synuclein.]
Figure 6. Single-molecule TIRF microscopy images of α-synuclein
released from the beads. Following incubation with imidazole, the α-
synuclein attached to the surface of the beads was eluted and imaged at
the single-molecule level. The HTM labeled α-synuclein and Cy5
labeled α-synuclein in the same ﬁeld of view are shown in panels (A)
and (C), respectively. The two channels are merged to give panel (B),
in which coincident spots corresponding to oligomers are clearly visible
(shown in yellow). Panels (D) and (E) show the same ﬁelds of view in
which only the coincident spots are shown in the HTM and Cy5
channels, respectively. Panel (E) shows a map of the oligomers
detected. (G) Two-dimensional (2D) contour plot showing the
number of Cy5 monomers and HTM monomers present in each
detected oligomer. (H) Size histogram of all the detected oligomers. (I)
Histogram of the natural logarithms of the stoichiometries of the
oligomers S = size(Cy5)/size(TMR).
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0.090 ± 0.007 (mean ± S.D., n = 3), indicating that 9% of the
Cy5 species detected were within a dual-labeled oligomer. By
measuring the total brightness in each channel and comparing
this with the mean brightness of the individual TMR or Cy5
ﬂuorophores, the number of monomer units of each α-synuclein
species in the oligomers can be calculated. The result from this
calculation is a 6 ± 1 ratio of Cy5 to TMR monomer units,
shown in the contour plot in Figure 6G. The sizes and natural
logarithms of the stoichiometries of the detected oligomers are
represented in the histograms in Figure 6H and Figure S3 in the
Supporting Information, respectively.
As described previously, ThT is able to bind to amyloid
structures, leading to an increase in its ﬂuorescence intensity by
several orders of magnitude, making it an unusually sensitive and
eﬃcient reporter of extended β-sheet structure. It has previously
been used with TIRFmicroscopy to detect individual aggregates
within bioﬂuids (single aggregate visualization by enhancement
(SAVE) imaging).31 In order to gain some insights into the
secondary structures of the on-bead oligomers, ThT was used to
determine whether any of the oligomers contained extended β-
sheet structure. The majority of oligomers detected were not
ThT-active, indicating that they are early aggregates in the ﬁbril-
formation pathway, as expected from the assay conditions. In 1.8
± 0.9% (mean ± S.D., n = 3) of the cases, however, there was
enough extended β-sheet structure for the oligomers to be
detected using ThT (see Figure S3 in the Supporting
Information), highlighting that some of the oligomers have
become more ﬁbril-like.17,31
α-Synuclein Aggregation Inhibitors. The objective of
this work was to develop an assay that (a) would allow
monitoring of the earliest stages of oligomerization of α-
synuclein, rather than later stage aggregation, and (b) is suitable
for drug screening. The ASYN-CONA assay has demonstrated
novel mechanistic insights into a so far undescribed oligome-
rization event. Given that the assay is reasonably miniaturized
and fast, it was concluded that, in a next step, it could be
investigated as a screening platform to ﬁnd novel α-synuclein
aggregation inhibitors. In order to validate ASYN-CONA as a
screening method, several known inhibitors of α-synuclein
aggregation were tested. Selegiline,48 curcumin,49,50 rifampi-
cin,49,51 dopamine,52,53 baicalein,54,55 and nicotine56,57 were the
natural products chosen to investigate their inhibitory properties
under the assay conditions described above. The on-bead
aggregation experiment was performed in the same way as
previously described with the compounds dissolved in EtOH
and added to the solution containing the beads with conjugated
α-synuclein-A91C-HTM and in solution α-synuclein-A91C-
Cy5. The aggregation of α-synuclein in the presence of the
inhibitors was followed as described above.
Figure 7 shows the mean bead ring intensity and the ratio,
representing the amount of aggregated α-synuclein-A91C-Cy5
onto on-bead α-synuclein-A91C-HTM after 5 h of incubation
with inhibitors. At a compound concentration of 50 μM, only
curcumin, baicalein, and rifampicin showed signiﬁcant inhib-
ition of α-synuclein aggregation. Most of the natural products
used in the assay have been described in the literature to induce
the formation of small nontoxic α-synuclein oligomers. α-
Synuclein aggregation has also been described as being very
dependent on the experimental conditions. The lack of an
inhibitory eﬀect of selegiline, dopamine, and nicotine, compared
to other published results, could be due to the detection of early
small oligomers with the ASYN-CONA assay, rather than the
detection of larger oligomers common in other assays.
Dopamine, selegiline, and nicotine may have more inhibitory
properties on an alternative aggregation pathway than that
observed on bead.
As a next step, the concentration dependence of the inhibitory
activity of the three active compounds (baicalein, curcumin, and
rifampicin) was assessed. The experiments were performed as
described above. In brief, beads with conjugated α-synuclein-
A91C-HTM were incubated with α-synuclein-A91C-Cy5 to
which either baicalein, curcumin, or rifampicin dissolved in
EtOH was added at diﬀerent concentrations. All three
compounds showed concentration dependent inhibition of
aggregation (Figure 8). Using the equation
= −
+
+
( )
y
I I
I
1 x
n
max min
IC
min
50
for curve ﬁtting, where y is the observed mean bead ring
intensity, Imax and Imin are the maximum and minimum mean
Figure 7. Activity of α-synuclein aggregation inhibitors assessed using
ASYN-CONA: (A) mean bead ring intensity quantiﬁed from the Cy5
ﬂuorescence detection channel and (B) ratio of the Cy5 ﬂuorescence
intensity to the TMR ﬂuorescence intensity. First, Ni-NTA agarose
beads were incubated with α-synuclein-A91C-HTM (100 nM), shaken
for 20min at 22 °C, and washed. α-Synuclein-A91C-Cy5 (500 nM) and
the inhibitor (50 μM) in EtOH (20%) were added to the solution and
the beads incubated for 5 h. One aliquot was taken after 5 h for imaging
and ﬂuorescence intensity quantiﬁcation. Three controls with,
respectively, no on-bead α-synuclein-A91C-HTM, no EtOH, or no
inhibitor present in the reaction sample were also included in the assay.
All experiments were performed in duplicate, and the full experiment
was repeated twice. The bars in graphs represent the average weighted
by the number of beads of the four repetitions.
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bead ring intensities, respectively, IC50 is the concentration of
the compound at which Imax was reduced by half, n is the slope of
the ﬁt, and x is the compound concentration, the IC50 for
curcumin was determined to be 2.76 ± 0.89 μM, the IC50 for
baicalein was 4.32 ± 0.60 μM, and the IC50 for rifampicin was
502.32 ± 360.36 μM.
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(38) Kostka, M.; Högen, T.; Danzer, K. M.; Levin, J.; Habeck, M.;
Wirth, A.; Wagner, R.; Glabe, C. G.; Finger, S.; Heinzelmann, U.;
Garidel, P.; Duan, W.; Ross, C. A.; Kretzschmar, H.; Giese, A. J. Biol.
Chem. 2008, 283 (16), 10992−11003.
(39) Uversky, V. N.; Li, J.; Fink, A. L. J. Biol. Chem. 2001, 276 (47),
44284−44296.
(40) Wagner, J.; Ryazanov, S.; Leonov, A.; Levin, J.; Shi, S.; Schmidt,
F.; Prix, C.; Pan-Montojo, F.; Bertsch, U.;Mitteregger-Kretzschmar, G.;
Geissen, M.; Eiden, M.; Leidel, F.; Hirschberger, T.; Deeg, A.; Krauth,
J.; Zinth,W.; Tavan, P.; Pilger, J.; Zweckstetter, M.; Frank, T.; Baḧr, M.;
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